

# Vaccine Adjuvants-EMEA Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/V52F7EF0620EN.html>

Date: December 2017

Pages: 139

Price: US\$ 3,480.00 (Single User License)

ID: V52F7EF0620EN

## Abstracts

### Report Summary

Vaccine Adjuvants-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Vaccine Adjuvants industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Whole EMEA and Regional Market Size of Vaccine Adjuvants 2013-2017, and development forecast 2018-2023

Main market players of Vaccine Adjuvants in EMEA, with company and product introduction, position in the Vaccine Adjuvants market

Market status and development trend of Vaccine Adjuvants by types and applications

Cost and profit status of Vaccine Adjuvants, and marketing status

Market growth drivers and challenges

The report segments the EMEA Vaccine Adjuvants market as:

EMEA Vaccine Adjuvants Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

Europe

Middle East

Africa

EMEA Vaccine Adjuvants Market: Product Type Segment Analysis (Consumption

Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Oral  
Subcutaneous  
Intramuscular  
Others

EMEA Vaccine Adjuvants Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Human Vaccine Adjuvants  
Research Applications  
Commercial Applications

EMEA Vaccine Adjuvants Market: Players Segment Analysis (Company and Product introduction, Vaccine Adjuvants Sales Volume, Revenue, Price and Gross Margin):

Brenntag Biosector  
Seppic  
CSL Limited  
Agenus  
Novavax  
Invivogen  
SPI Pharma  
Avanti Polar Lipids  
MPV Technologies  
OZ Biosciences

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

## Contents

### **CHAPTER 1 OVERVIEW OF VACCINE ADJUVANTS**

- 1.1 Definition of Vaccine Adjuvants in This Report
- 1.2 Commercial Types of Vaccine Adjuvants
  - 1.2.1 Oral
  - 1.2.2 Subcutaneous
  - 1.2.3 Intramuscular
  - 1.2.4 Others
- 1.3 Downstream Application of Vaccine Adjuvants
  - 1.3.1 Human Vaccine Adjuvants
  - 1.3.2 Research Applications
  - 1.3.3 Commercial Applications
- 1.4 Development History of Vaccine Adjuvants
- 1.5 Market Status and Trend of Vaccine Adjuvants 2013-2023
  - 1.5.1 EMEA Vaccine Adjuvants Market Status and Trend 2013-2023
  - 1.5.2 Regional Vaccine Adjuvants Market Status and Trend 2013-2023

### **CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS**

- 2.1 Market Status of Vaccine Adjuvants in EMEA 2013-2017
- 2.2 Consumption Market of Vaccine Adjuvants in EMEA by Regions
  - 2.2.1 Consumption Volume of Vaccine Adjuvants in EMEA by Regions
  - 2.2.2 Revenue of Vaccine Adjuvants in EMEA by Regions
- 2.3 Market Analysis of Vaccine Adjuvants in EMEA by Regions
  - 2.3.1 Market Analysis of Vaccine Adjuvants in Europe 2013-2017
  - 2.3.2 Market Analysis of Vaccine Adjuvants in Middle East 2013-2017
  - 2.3.3 Market Analysis of Vaccine Adjuvants in Africa 2013-2017
- 2.4 Market Development Forecast of Vaccine Adjuvants in EMEA 2018-2023
  - 2.4.1 Market Development Forecast of Vaccine Adjuvants in EMEA 2018-2023
  - 2.4.2 Market Development Forecast of Vaccine Adjuvants by Regions 2018-2023

### **CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES**

- 3.1 Whole EMEA Market Status by Types
  - 3.1.1 Consumption Volume of Vaccine Adjuvants in EMEA by Types
  - 3.1.2 Revenue of Vaccine Adjuvants in EMEA by Types
- 3.2 EMEA Market Status by Types in Major Countries

- 3.2.1 Market Status by Types in Europe
- 3.2.2 Market Status by Types in Middle East
- 3.2.3 Market Status by Types in Africa
- 3.3 Market Forecast of Vaccine Adjuvants in EMEA by Types

## **CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY**

- 4.1 Demand Volume of Vaccine Adjuvants in EMEA by Downstream Industry
- 4.2 Demand Volume of Vaccine Adjuvants by Downstream Industry in Major Countries
  - 4.2.1 Demand Volume of Vaccine Adjuvants by Downstream Industry in Europe
  - 4.2.2 Demand Volume of Vaccine Adjuvants by Downstream Industry in Middle East
  - 4.2.3 Demand Volume of Vaccine Adjuvants by Downstream Industry in Africa
- 4.3 Market Forecast of Vaccine Adjuvants in EMEA by Downstream Industry

## **CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF VACCINE ADJUVANTS**

- 5.1 EMEA Economy Situation and Trend Overview
- 5.2 Vaccine Adjuvants Downstream Industry Situation and Trend Overview

## **CHAPTER 6 VACCINE ADJUVANTS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA**

- 6.1 Sales Volume of Vaccine Adjuvants in EMEA by Major Players
- 6.2 Revenue of Vaccine Adjuvants in EMEA by Major Players
- 6.3 Basic Information of Vaccine Adjuvants by Major Players
  - 6.3.1 Headquarters Location and Established Time of Vaccine Adjuvants Major Players
  - 6.3.2 Employees and Revenue Level of Vaccine Adjuvants Major Players
- 6.4 Market Competition News and Trend
  - 6.4.1 Merger, Consolidation or Acquisition News
  - 6.4.2 Investment or Disinvestment News
  - 6.4.3 New Product Development and Launch

## **CHAPTER 7 VACCINE ADJUVANTS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA**

- 7.1 Brenntag Biosector
  - 7.1.1 Company profile

- 7.1.2 Representative Vaccine Adjuvants Product
- 7.1.3 Vaccine Adjuvants Sales, Revenue, Price and Gross Margin of Brenntag  
Biosector
- 7.2 Seppic
  - 7.2.1 Company profile
  - 7.2.2 Representative Vaccine Adjuvants Product
  - 7.2.3 Vaccine Adjuvants Sales, Revenue, Price and Gross Margin of Seppic
- 7.3 CSL Limited
  - 7.3.1 Company profile
  - 7.3.2 Representative Vaccine Adjuvants Product
  - 7.3.3 Vaccine Adjuvants Sales, Revenue, Price and Gross Margin of CSL Limited
- 7.4 Agenus
  - 7.4.1 Company profile
  - 7.4.2 Representative Vaccine Adjuvants Product
  - 7.4.3 Vaccine Adjuvants Sales, Revenue, Price and Gross Margin of Agenus
- 7.5 Novavax
  - 7.5.1 Company profile
  - 7.5.2 Representative Vaccine Adjuvants Product
  - 7.5.3 Vaccine Adjuvants Sales, Revenue, Price and Gross Margin of Novavax
- 7.6 Invivogen
  - 7.6.1 Company profile
  - 7.6.2 Representative Vaccine Adjuvants Product
  - 7.6.3 Vaccine Adjuvants Sales, Revenue, Price and Gross Margin of Invivogen
- 7.7 SPI Pharma
  - 7.7.1 Company profile
  - 7.7.2 Representative Vaccine Adjuvants Product
  - 7.7.3 Vaccine Adjuvants Sales, Revenue, Price and Gross Margin of SPI Pharma
- 7.8 Avanti Polar Lipids
  - 7.8.1 Company profile
  - 7.8.2 Representative Vaccine Adjuvants Product
  - 7.8.3 Vaccine Adjuvants Sales, Revenue, Price and Gross Margin of Avanti Polar  
Lipids
- 7.9 MPV Technologies
  - 7.9.1 Company profile
  - 7.9.2 Representative Vaccine Adjuvants Product
  - 7.9.3 Vaccine Adjuvants Sales, Revenue, Price and Gross Margin of MPV  
Technologies
- 7.10 OZ Biosciences
  - 7.10.1 Company profile

7.10.2 Representative Vaccine Adjuvants Product

7.10.3 Vaccine Adjuvants Sales, Revenue, Price and Gross Margin of OZ Biosciences

## **CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF VACCINE ADJUVANTS**

8.1 Industry Chain of Vaccine Adjuvants

8.2 Upstream Market and Representative Companies Analysis

8.3 Downstream Market and Representative Companies Analysis

## **CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF VACCINE ADJUVANTS**

9.1 Cost Structure Analysis of Vaccine Adjuvants

9.2 Raw Materials Cost Analysis of Vaccine Adjuvants

9.3 Labor Cost Analysis of Vaccine Adjuvants

9.4 Manufacturing Expenses Analysis of Vaccine Adjuvants

## **CHAPTER 10 MARKETING STATUS ANALYSIS OF VACCINE ADJUVANTS**

10.1 Marketing Channel

10.1.1 Direct Marketing

10.1.2 Indirect Marketing

10.1.3 Marketing Channel Development Trend

10.2 Market Positioning

10.2.1 Pricing Strategy

10.2.2 Brand Strategy

10.2.3 Target Client

10.3 Distributors/Traders List

## **CHAPTER 11 REPORT CONCLUSION**

## **CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE**

12.1 Methodology/Research Approach

12.1.1 Research Programs/Design

12.1.2 Market Size Estimation

12.1.3 Market Breakdown and Data Triangulation

12.2 Data Source

12.2.1 Secondary Sources

12.2.2 Primary Sources  
12.3 Reference

## I would like to order

Product name: Vaccine Adjuvants-EMEA Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/V52F7EF0620EN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/V52F7EF0620EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970